Tuesday, July 10, 2018

Pharma Reviews: Aurobindo in last lap to buy Mallinckrodt's US generics business

In May, India's third-largest drug maker Lupin made an impairment provision of Rs 1,400 crore for Gavis Pharma, a company it had bought for $880 ...
Read more: Aurobindo in last lap to buy Mallinckrodt's US generics business